These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31647577)

  • 1. Efficacy, Tolerability, and Safety of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study.
    Lipton RB; Munjal S; Brand-Schieber E; Tepper SJ; Dodick DW
    Headache; 2020 Jan; 60(1):58-70. PubMed ID: 31647577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study.
    Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
    Headache; 2018 May; 58(5):676-687. PubMed ID: 29878341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study.
    Landy S; Munjal S; Brand-Schieber E; Rapoport AM
    J Headache Pain; 2018 Aug; 19(1):69. PubMed ID: 30112726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute Treatment of Migraine with Celecoxib Oral Solution: Results of a Randomized, Placebo-Controlled Clinical Trial.
    Lipton RB; Munjal S; Dodick DW; Tepper SJ; Serrano D; Iaconangelo C
    J Pain Res; 2021; 14():549-560. PubMed ID: 33658842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Tolerability, and Safety of Celecoxib Oral Solution (ELYXYB) in Acute Treatment of Episodic Migraine with or without Aura.
    Lipton RB; Munjal S; Tepper SJ; Iaconangelo C; Serrano D
    J Pain Res; 2021; 14():2529-2542. PubMed ID: 34447267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study.
    Landy S; Munjal S; Brand-Schieber E; Rapoport AM
    J Headache Pain; 2018 Aug; 19(1):70. PubMed ID: 30112725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment.
    Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
    CNS Drugs; 2019 Apr; 33(4):375-382. PubMed ID: 30877622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of DFN-15, an oral liquid formulation of celecoxib, in adults with migraine: a multicenter, randomized, placebo-controlled, double-blind, crossover study.
    Munjal S; Bennett A
    Neuropsychiatr Dis Treat; 2017; 13():2797-2802. PubMed ID: 29158678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine.
    Cady RK; Munjal S; Cady RJ; Manley HR; Brand-Schieber E
    J Headache Pain; 2017 Dec; 18(1):17. PubMed ID: 28176235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered
    Silberstein S; Winner PK; McAllister PJ; Tepper SJ; Halker R; Mahmoud RA; Siffert J
    Headache; 2017 Jun; 57(6):862-876. PubMed ID: 28497569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial.
    Croop R; Madonia J; Stock DA; Thiry A; Forshaw M; Murphy A; Coric V; Lipton RB
    Headache; 2022 Oct; 62(9):1153-1163. PubMed ID: 36239038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous ibuprofen for acute treatment of migraine: A double-blind, randomized, placebo-controlled pilot study.
    Yuan H; Curran JG; Keith SW; Hopkins MM; Silberstein SD
    Headache; 2021 Oct; 61(9):1432-1440. PubMed ID: 34601736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
    Croop R; Goadsby PJ; Stock DA; Conway CM; Forshaw M; Stock EG; Coric V; Lipton RB
    Lancet; 2019 Aug; 394(10200):737-745. PubMed ID: 31311674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study.
    Derosier F; Sheftell F; Silberstein S; Cady R; Ruoff G; Krishen A; Peykamian M
    Headache; 2012 Apr; 52(4):530-43. PubMed ID: 22103635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks.
    Tepper SJ; Vasudeva R; Krege JH; Rathmann SS; Doty E; Vargas BB; Magis D; Komori M
    Headache; 2020 Sep; 60(8):1601-1615. PubMed ID: 32634275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult-to-Treat Migraine Headaches.
    Tepper SJ; Dodick DW; Schmidt PC; Kellerman DJ
    Headache; 2019 Apr; 59(4):509-517. PubMed ID: 30698272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, celecoxib- and placebo-controlled study of the effectiveness of CS-706 in acute postoperative dental pain.
    Moberly JB; Xu J; Desjardins PJ; Daniels SE; Bandy DP; Lawson JE; Link AJ; Truitt KE
    Clin Ther; 2007 Mar; 29(3):399-412. PubMed ID: 17577461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial.
    Winner PK; McAllister P; Chakhava G; Ailani J; Ettrup A; Krog Josiassen M; Lindsten A; Mehta L; Cady R
    JAMA; 2021 Jun; 325(23):2348-2356. PubMed ID: 34128999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.
    Lipton RB; Dodick DW; Ailani J; Lu K; Finnegan M; Szegedi A; Trugman JM
    JAMA; 2019 Nov; 322(19):1887-1898. PubMed ID: 31742631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial.
    Yu S; Guo A; Wang Z; Liu J; Tan G; Yang Q; Zhang M; Yibulaiyin H; Chen H; Zhang Y; Croop R; Sun Y; Liu Y; Zhao Q; Lu Z
    J Headache Pain; 2024 Apr; 25(1):57. PubMed ID: 38627638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.